Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation.
Chemotherapy in osteosarcoma has had a major impact in attaining metastasis-free survival, and the cure rates with the use of modern regimens range from 65% to 75%. Preoperative chemotherapy has facilitated surgical resection of the primary tumor, rendering increased numbers of candidates for limb salvage. The effects on the primary tumor may be used as a predictive factor in determining outcome.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D008727:Methotrexate / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D012516:Osteosarcoma / Q000188:drug therapy* / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate